")}("position","absolute",["\/lib\/bootstrap\/dist\/css\/bootstrap.min.css"],"rel=\u0022stylesheet\u0022 ");
Published On: Wednesday, June 2, 2021 | By: Team KnowMyStock
"The capital infusion plan should help PNB HF to refocus on growth after six quarters of loan book contraction. However, as it’s likely to continue shedding its wholesale book (16 per cent of AUM), net balance sheet growth will take longer to come through even as disbursements pick up in the retail loan portfolio (Loan Against Property or LAP and affordable)," say analysts.
The highest target price on the stock (Rs 678) is 2 per cent below its current price, while the lowest price (Rs 575) is 17 per cent below its CMP.
Considering the its LAP (26 per cent of loans including non-residential premises) and other factors, analysts expect PNB HF’s earnings per share (EPS) and book value per share to drop going ahead.
Follow Us On: